logo
Epilepsy May Signal Future Dementia Risk

Epilepsy May Signal Future Dementia Risk

Medscape4 hours ago

Epilepsy prevalence was significantly higher among people with frontotemporal dementia (FTD) than among those with Alzheimer's disease (AD), a new study showed, with epilepsy occurring in some cases up to 10 years before an FTD diagnosis.
METHODOLOGY:
In a case-control study in Finland, epilepsy prevalence and antiseizure medicine ( ASM) purchases were compared between 245 patients with FTD (mean age at diagnosis, 65 years; 49% women), more than 1300 patients with AD (mean age, 72 years; 59% women), and more than 2400 individuals matched for age, sex, and location to act as the healthy control group (mean age, 65 years; 49% women).
Data were collected from 2010 to 2021, and epilepsy cases were identified using codes from the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10).
Purchases of ASMs were tracked throughout the study period, and epilepsy prevalence was evaluated at four timepoints: 10 years before the diagnosis of FTD, 5 years before diagnosis, at diagnosis, and 5 years after diagnosis.
TAKEAWAY:
Both epilepsy prevalence and ASM purchases were significantly greater in patients with FTD than in those in the healthy control group at all timepoints ( P < .001 for both measures).
< .001 for both measures). Epilepsy prevalence was significantly higher in patients with FTD than in patients with AD 10 years before ( P = .03), 5 years before ( P = .002), and 5 years after ( P = .05) the diagnosis of FTD.
= .03), 5 years before ( = .002), and 5 years after ( = .05) the diagnosis of FTD. The prevalence of ASM use was also significantly higher among patients with FTD than among patients with AD ( P = .004 at 5 years before FTD diagnosis and P < .001 at other timepoints).
= .004 at 5 years before FTD diagnosis and < .001 at other timepoints). After adjusting for age at the time of FTD diagnosis, the risk for mortality was not significantly different between patients with both FTD and epilepsy and those without epilepsy.
IN PRACTICE:
'It is noteworthy that epilepsy occurred in some patients with FTD already 10 years before their dementia diagnosis, and it was more common in all the examined stages of the disease than previous international studies have reported,' lead investigator Annemari Kilpeläinen, MD, Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland, said in a press release.
The researchers added that 'enhancing knowledge of the comorbidity between epilepsy and FTD could lead to more precise and comprehensive diagnostics and treatment of these conditions as well as new pathophysiologic findings.'
SOURCE:
The study was published online on June 2 in JAMA Neurology .
LIMITATIONS:
This study was limited by reliance on ICD-10 codes for classification of epilepsy types and included only two major provinces in Finland. Additionally, epilepsy diagnoses recorded before 1998 may have been missed.
DISCLOSURES:
This study was part of the Real-World Data Project on Neurodegenerative Diseases, funded by Roche OY. Additional funding was provided by the Kuopio University Hospital, the Finnish Brain Foundation, the Uulo Arhio Foundation, the Finnish Medical Foundation, the Finnish Cultural Foundation, the Wihuri Foundation, and the Sigrid Juselius Foundation. Several investigators reported having ties with various organizations and pharmaceutical companies. Full details are provided in the original article.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Spain Says Failure to Control Voltage Caused April Blackout
Spain Says Failure to Control Voltage Caused April Blackout

Bloomberg

timean hour ago

  • Bloomberg

Spain Says Failure to Control Voltage Caused April Blackout

Spain has identified the causes of the historic April 28 electricity outage and signaled that it was due to a lack of capacity to control voltage changes. Spain's power grid 'didn't have enough capacity' to control voltage prior to the blackout, partly because generation plants that should have been helping to regulate voltage weren't operating, Environmental Minister Sara Aagesen said in a press conference Tuesday. She didn't say why this happened.

Higher Liothyronine Use in Hypothyroidism With Psych History
Higher Liothyronine Use in Hypothyroidism With Psych History

Medscape

timean hour ago

  • Medscape

Higher Liothyronine Use in Hypothyroidism With Psych History

Patients with a psychiatric history prior to their diagnosis of autoimmune hypothyroidism were nearly twice as likely to receive liothyronine treatment as those without such a history, with the effect being most pronounced among those with a history of affective or anxiety disorders. METHODOLOGY: Researchers in Sweden conducted a retrospective, population-based cohort study using national registry data to assess the association between prior psychiatric history and subsequent liothyronine use in patients with autoimmune hypothyroidism. They analysed 353,708 adults who filled at least one prescription for thyroid hormone replacement (liothyronine or levothyroxine) between 2006 and 2020, of whom 44.8% had psychiatric morbidity before the first thyroid hormone prescription. Among patients with a history of psychiatric morbidity, 96.7% were exposed to affective or anxiety morbidity and 8.3% had a history of psychotic disorders. The primary endpoint was liothyronine therapy at any point during the median follow-up duration of 63.4 months for patients with prior psychiatric morbidity and 69.2 months for those without. TAKEAWAY: Overall, 3.6% of patients received liothyronine during the study period. Patients with a history of psychiatric morbidity were more likely to receive liothyronine therapy than those without it (adjusted odds ratio [aOR], 1.90; P < .001). < .001). The strongest association with liothyronine therapy was observed in patients with a history of affective and anxiety disorders (aOR, 1.91; P < .001), whereas no significant difference was found between those with a history of psychotic disorders and those without ( P = .11). IN PRACTICE: "This study provides empirical evidence that patients with autoimmune hypothyroidism and a history of psychiatric morbidity are more likely to receive LT3 [liothyronine]-treatment, especially among those with affective or anxiety morbidity," the authors wrote. "This may reflect lingering symptoms that influence treatment decisions of hypothyroidism, either due to symptoms being misinterpreted as treatment-resistant hypothyroidism or actual physiological differences in thyroid disease within this group," they added. SOURCE: This study was led by Fredric Hedberg, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. It was published online on June 07, 2025, in The Journal of Clinical Endocrinology & Metabolism . LIMITATIONS: The retrospective design limited the ability to establish causal relationships. Data on thyroid hormone concentrations and treatment indications were lacking, preventing the determination of whether liothyronine prescriptions were due to laboratory abnormalities, persistent symptoms, or physician preferences. Moreover, information on interferon and immune checkpoint inhibitor therapies was unavailable. DISCLOSURES: This study was supported by grants from the Region Stockholm Drug and Therapeutic Committee and the Lisa and Johan Grönberg Foundation. The authors declared having no competing interests.

Metformin Timing and Pregnancy Outcomes in PCOS
Metformin Timing and Pregnancy Outcomes in PCOS

Medscape

timean hour ago

  • Medscape

Metformin Timing and Pregnancy Outcomes in PCOS

For women with polycystic ovary syndrome (PCOS), continuing preconception metformin throughout the first trimester rather than stopping it at the positive pregnancy test might reduce the risk for miscarriage and improve pregnancy outcomes. METHODOLOGY: Researchers conducted a meta-analysis by searching the literature across MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials databases to determine how the timing of metformin treatment specifically affects pregnancy outcomes in women with PCOS. They included 12 randomised controlled trials including 1708 women with PCOS and compared preconception metformin, continued until at least pregnancy confirmation, with placebo or no treatment. The primary outcome was the miscarriage rate; secondary outcomes were the clinical pregnancy rate and live birth rate. Indirect comparisons between continuing metformin throughout the first trimester and stopping it at pregnancy confirmation were performed using the Bucher technique to evaluate key pregnancy outcomes. TAKEAWAY: Women who continued preconception metformin throughout the first trimester had a lower risk for miscarriage (odds ratio [OR], 0.64; 95% CI, 0.32-1.25) and higher clinical pregnancy rates (OR, 1.57; 95% CI, 1.11-2.23) and live birth rates (OR, 1.24; 95% CI, 0.59-2.61) than those who received either placebo or no treatment. Women who stopped metformin at pregnancy confirmation showed a higher risk for miscarriage (OR, 1.46; 95% CI, 0.73-2.90) and higher clinical pregnancy rates (OR, 1.35; 95% CI, 1.01-1.80) than those who received either placebo or no treatment. Women who continued metformin throughout the first trimester experienced a lower risk for miscarriage (OR, 0.44; 95% CI, 0.17-1.16) and higher clinical pregnancy rates (OR, 1.16; 95% CI, 0.74-1.83) and live birth rates (OR, 1.14; 95% CI, 0.41-3.13) than those who stopped metformin at the positive pregnancy test. IN PRACTICE: "The [study] findings suggest that discontinuing metformin upon pregnancy confirmation may cause a delayed 'rebound' effect, potentially increasing insulin resistance and adversely affecting pregnancy outcomes later in the first trimester," the authors wrote. SOURCE: This study was led by James Cheshire, PhD, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, England. It was published online on June 03, 2025, in the American Journal of Obstetrics and Gynecology . LIMITATIONS: The major limitation of this study was the heterogeneous nature of the population and the overall low quality of evidence. Findings may not be applicable to all PCOS phenotypes as the study did not account for differences in phenotypes and degrees of hyperandrogenism and insulin resistance in women with PCOS. Many studies did not stratify pregnancy outcome data on the basis of BMI, preventing meaningful subgroup analyses and potentially affecting the findings. DISCLOSURES: This study did not receive any external funding. The authors declared having no competing interests.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store